Findings Indicate Consistently Accurate Performance During Motion of the
Nellcor N-395. P.I. Michael W. Jopling, M.D., Ohio State University, Presented
Results at Society for Technology in Anesthesia Annual Conference.
ST. LOUIS, Jan. 20 /PRNewswire/ -- Mallinckrodt Inc. (NYSE: MKG) today
announced the published results of its most recent sponsored scientific study
comparing pulse oximetry technologies led by Michael W. Jopling, M.D., who is
affiliated with St. Ann's Hospital and Ohio State University. Dr. Jopling
evaluated the effects of motion during certain controlled hypoxia on three
currently marketed pulse oximetry products. The results were presented at the
Society for Technology in Anesthesia Conference in Lake Buena Vista, Fl.,
January 13, 2000.
Dr. Jopling evaluated the Nellcor(R) N-395 Pulse Oximeter with Oxismart(R)
XL Advanced Signal Processing, the Nellcor NPB-290 with Oxismart and the Ivy
2000 with Masimo SET(R) technologies. In each of the three studies conducted,
Dr. Jopling found the N-395 performance to be more accurate for arterial
oxygen saturation during motion.
"I'm pleased medical manufacturers are beginning to make major
improvements in the algorithms used to acquire patient data," said
Dr. Jopling. "Up to now, improvements have been mostly cosmetic: device size,
cost and user interface issues. Now we are starting to see real improvements
in monitor performance. Oxygen saturation is a parameter in which all
clinicians expect a high level of performance and accuracy. This research was
conducted to help provide a practical benchmark for evaluating pulse oximetry
technologies."
The studies evaluated the performance of the three pulse oximeters on
three separate adult test populations under varying degrees of motion and
changing or stable saturation levels. Motion comprised voluntary movements of
varying intensity, designed to mimic conditions commonly encountered in a
clinical environment. In all three studies, the N-395 more accurately
reflected SpO2 values as compared to a non-moving reference oximeter.
Dr. Jopling evaluated precision and the degree to which the oximeter posted
erroneous values in excess of clinically relevant levels. In all three
studies, the N-395 demonstrated significantly better precision and error rates
than the Ivy 2000/Masimo or NPB-290 oximeters. During the severe motion
protocol, the N-395 demonstrated nearly half the error rate when compared to
the Ivy 2000/Masimo oximeter. The Ivy 2000/Masimo and NPB-290 oximeters were
observed to be similar in their performance.
About Mallinckrodt
Mallinckrodt Inc. is a global manufacturer and marketer of healthcare
products. Based in St. Louis, Mo., the company has three product groups:
Respiratory, Imaging and Pharmaceuticals.
The Respiratory Group develops, manufactures and markets products that
help diagnose, monitor, and treat respiratory and anesthesiology patients
across the continuum of care. The Respiratory Group is a world leader in
pulse oximeters and sensors, airway management products, ventilators and
alternate care products.
Mallinckrodt operates in more than 100 countries and had fiscal 1999 net
sales of $2.6 billion. The Mallinckrodt web site address is
http://www.mallinckrodt.com.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
Company News On-Call:
http://www.prnewswire.com/comp/440950.html or fax,
800-758-5804, ext. 440950
CONTACT:
Barbara Abbett of Mallinckrodt Inc.,
314-654-5230, barbara.abbett@mkg.com, or Gil Isenstein of Mullen,
978-468-1155 ext. 3111, gisenstein@mullen.com
|
